[{"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 28, "maxAge": 86400, "priceHint": 4, "previousClose": 2.52, "open": 2.57, "dayLow": 2.37, "dayHigh": 2.59, "regularMarketPreviousClose": 2.52, "regularMarketOpen": 2.57, "regularMarketDayLow": 2.37, "regularMarketDayHigh": 2.59, "beta": 1.64, "forwardPE": -3.3466666, "volume": 4207051, "regularMarketVolume": 4207051, "averageVolume": 517098, "averageVolume10days": 874520, "averageDailyVolume10Day": 874520, "bid": 2.46, "ask": 2.52, "bidSize": 100, "askSize": 100, "marketCap": 164319408, "fiftyTwoWeekLow": 1.08, "fiftyTwoWeekHigh": 3.79, "fiftyDayAverage": 2.2996, "twoHundredDayAverage": 1.73175, "currency": "USD", "enterpriseValue": 68908352, "floatShares": 42962636, "sharesOutstanding": 65465900, "sharesShort": 2882838, "sharesShortPriorMonth": 6274945, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.044, "heldPercentInsiders": 0.01684, "heldPercentInstitutions": 0.90810996, "shortRatio": 7.15, "shortPercentOfFloat": 0.055999998, "impliedSharesOutstanding": 65465900, "bookValue": 1.643, "priceToBook": 1.5276933, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -31367000, "trailingEps": -1.45, "forwardEps": -0.75, "pegRatio": -0.1, "lastSplitFactor": "1:10", "lastSplitDate": 1656460800, "enterpriseToEbitda": -2.133, "52WeekChange": 0.8731344, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RGLS", "underlyingSymbol": "RGLS", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "firstTradeDateEpochUtc": 1349789400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cd43addf-be3b-3da4-8113-29f5cb221300", "messageBoardId": "finmb_36742485", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.51, "targetHighPrice": 11.0, "targetLowPrice": 3.0, "targetMeanPrice": 7.4, "targetMedianPrice": 8.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 97554000, "totalCashPerShare": 1.49, "ebitda": -32306000, "totalDebt": 2138000, "quickRatio": 17.169, "currentRatio": 17.854, "debtToEquity": 1.987, "returnOnAssets": -0.26931, "returnOnEquity": -0.46752998, "freeCashflow": -17540250, "operatingCashflow": -27396000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]